{"id":1385,"date":"2026-09-08T23:01:03","date_gmt":"2026-09-08T15:01:03","guid":{"rendered":"http:\/\/www.puriactives.com\/en\/?p=1385"},"modified":"2026-09-08T23:01:03","modified_gmt":"2026-09-08T15:01:03","slug":"nanoactiveretinal-bakuchiol-%e7%ba%b3%e7%b1%b3%e5%8c%85%e8%a3%b9%e8%a7%86%e9%bb%84%e9%86%9b%ef%bc%8d%e8%a1%a5%e9%aa%a8%e8%84%82%e9%85%9a","status":"publish","type":"post","link":"http:\/\/www.puriactives.com\/en\/?p=1385","title":{"rendered":"NanoActive™Retinal \u2013 Bakuchiol \u7eb3\u7c73\u5305\u88f9\u89c6\u9ec4\u919b\uff0d\u8865\u9aa8\u8102\u915a"},"content":{"rendered":"

NanoActive™Retinal \u2013 Bakuchiol<\/h2>\n

Nano-Encapsulated Retinal\u2013Bakuchiol<\/p>\n

Dual-Pathway Retinoid Renewal \u00b7 Nano-Delivery Technology<\/p>\n

INCI NAME \u2014 RETINAL, BAKUCHIOL<\/p>\n

PuriPharm Co. Ltd. \u00b7 Technical Marketing Presentation<\/p>\n

02 \u00b7 RETINOID CARE \u2014 THE NEXT CHAPTER<\/p>\n

Retinoid Care Is Entering Its Next Stage<\/h2>\n

Retinoids remain the most evidence-supported active family for managing skin photoaging. The questions facing brands and formulators have moved beyond whether a formula contains a retinoid to four more fundamental issues: Can the active be converted efficiently? Can it remain stable? Can consumers sustain long-term use? Does the formula provide sufficient design freedom?<\/p>\n\n\n\n\n\n\n\n
Core question<\/th>\nExplanation<\/th>\n<\/tr>\n
01 Efficacy<\/td>\nRetinoids must be converted to retinoic acid to act; the conversion pathway determines the speed and intensity of activity.<\/td>\n<\/tr>\n
02 Stability<\/td>\nHigh activity comes with sensitivity to light and oxygen; active retention during shelf life and in-formula is essential.<\/td>\n<\/tr>\n
03 Tolerance<\/td>\nIrritation determines adherence, and adherence determines whether long-term benefits can be realized.<\/td>\n<\/tr>\n
04 Formulation<\/td>\nDosage form, sensory profile and system compatibility define the space for product differentiation.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The next-stage answer: advanced actives \u00d7 complementary mechanisms \u00d7 nano delivery.<\/p>\n

03 \u00b7 PRODUCT OVERVIEW<\/p>\n

NanoActive™ Retinal-Bakuchiol<\/h2>\n\n\n\n\n\n\n\n
Identity<\/th>\nInformation<\/th>\n<\/tr>\n
Product name<\/td>\nNano-Encapsulated Retinal\u2013Bakuchiol<\/td>\n<\/tr>\n
INCI name<\/td>\nRetinal, Bakuchiol<\/td>\n<\/tr>\n
Technology platform<\/td>\nNanoActive™ nano-encapsulation and delivery system<\/td>\n<\/tr>\n
Application settings<\/td>\nDual use across skin care and scalp care<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
01<\/td>\nBiology: Retinal is the direct precursor of retinoic acid; one oxidation step drives advanced retinoid biology.<\/td>\n<\/tr>\n
02<\/td>\nSynergy: Bakuchiol supports retinol-like gene expression, antioxidant defense, inflammatory modulation, extracellular-matrix biology and skin homeostasis.<\/td>\n<\/tr>\n
03<\/td>\nDelivery: NanoActive™ improves protection, dispersion, formulation suitability and delivery performance for sensitive actives.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

This is not a simple ingredient blend. It is a next-generation dual-pathway renewal platform integrating high-efficiency renewal, complementary mechanisms, nano delivery and both skin and scalp applications.<\/p>\n

04 \u00b7 01 \u00b7 BIOLOGY \u2014 RETINAL<\/p>\n

Why Retinal: Closer to the Active EndpointRetinyl esters \u2192 Retinol \u2192 Retinal \u2192 Retinoic acid<\/h2>\n\n\n\n\n\n\n\n
Metabolic node<\/th>\nDescription<\/th>\n<\/tr>\n
Retinyl esters<\/td>\nStorage form; hydrolyzed to retinol.<\/td>\n<\/tr>\n
Retinol<\/td>\nRequires a rate-limiting oxidation step to form retinal.<\/td>\n<\/tr>\n
Retinal<\/td>\nAn advanced cosmetic retinoid that requires only one oxidation step to form retinoic acid.<\/td>\n<\/tr>\n
Retinoic acid<\/td>\nThe active retinoid endpoint; a drug active not permitted as a cosmetic ingredient.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
Key advantage<\/th>\nData and significance<\/th>\n<\/tr>\n
Approximately 3\u00d7 biological activity<\/td>\nBypassing retinol’s first rate-limiting oxidation step gives retinal approximately three times the retinoid biological activity of retinol.<\/td>\n<\/tr>\n
At least 11\u00d7 faster conversion<\/td>\nConversion of retinal to retinoic acid is estimated to be more than 11 times faster than the retinol pathway and occurs in both differentiated and undifferentiated keratinocytes.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Retinal is the direct precursor of retinoic acid\u2014an advanced retinoid positioned closer to the active endpoint.<\/p>\n

Siegenthaler G, Saurat JH, Ponec M. Biochem J. 1990;268(2):371\u2013378. | Brown A, et al. Dermatol Ther (Heidelb). 2023;13(10):2299\u20132317.<\/p>\n

05 \u00b7 01 \u00b7 BIOLOGY \u2014 ADVANCED RETINOID BIOLOGY<\/p>\n

One Oxidation Step Directly Drives Classical Retinoid SignalingRetinal \u2192 one-step oxidation \u2192 retinoic acid \u2192 RAR\/RXR nuclear receptors \u2192 target-gene transcription \u2192 visible epidermal and dermal renewal<\/h2>\n\n\n\n\n\n\n
01<\/td>\nRetinal undergoes one oxidation step inside keratinocytes to form retinoic acid.<\/td>\n<\/tr>\n
02<\/td>\nRetinoic acid binds nuclear RAR receptors and forms heterodimers with RXR.<\/td>\n<\/tr>\n
03<\/td>\nRAR-RXR binds promoter regions and regulates target genes involved in skin biology.<\/td>\n<\/tr>\n
04<\/td>\nThe result is visible renewal across both the epidermis and dermis.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
Level<\/th>\nBiological effects<\/th>\n<\/tr>\n
Epidermis<\/td>\nAccelerated epidermal renewal; regulation of keratinocyte differentiation; increased epidermal thickness; upregulation of RA-activity markers such as CRABP-II; regulation of barrier- and hydration-related genes; improved desquamation, texture refinement and tone uniformity.<\/td>\n<\/tr>\n
Dermis<\/td>\nSupport for fibroblast function and extracellular-matrix remodeling; new collagen deposition; inhibition of UV-induced MMP-related matrix degradation; restoration of the elastic-fiber network; visible outcomes in wrinkles, texture, laxity and photoaging pigmentation.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A complete retinoid-biology pathway drives systematic renewal from the epidermis to the dermis.<\/p>\n

Saurat JH, et al. J Invest Dermatol. 1994;103(6):770\u2013774. | Fisher GJ, et al. Nature. 1996;379(6563):335\u2013339. | Xiao JH, et al. J Biol Chem. 1995;270(7):3001\u20133010.<\/p>\n

06 \u00b7 01 \u00b7 BIOLOGY \u2014 EPIDERMIS TO DERMIS<\/p>\n

Retinal: From Epidermal Renewal to Dermal RemodelingEpidermis: renewal, differentiation, thickness and texture; Dermis: fibroblasts, collagen, elastic fibers, ECM and MMP management<\/h2>\n\n\n\n\n\n\n
Evidence<\/th>\nFinding<\/th>\n<\/tr>\n
Human study: epidermis and elasticity<\/td>\nAfter one year of 0.05% retinaldehyde, high-resolution ultrasound and rheological measurements showed significant increases in epidermal thickness and skin elasticity (p < 0.01), with a trend toward increased dermal thickness.<\/td>\n<\/tr>\n
Ex vivo: repair of UVA damage<\/td>\nIn a UVA-photodamaged human skin model, two weeks of 0.05% retinaldehyde restored elastic fibers and collagen to levels close to non-photodamaged skin.<\/td>\n<\/tr>\n
Biological effects in human skin<\/td>\nTopical retinaldehyde induced typical retinoid effects, including epidermal thickening and CRABP-II expression, while maintaining good tolerance.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Metabolic position \u2192 retinoid biology \u2192 epidermal renewal \u2192 ECM\/collagen\/elastin support \u2192 visible human outcomes: one complete evidence chain.<\/p>\n

Diridollou S, et al. Dermatology. 1999;199(Suppl 1):37\u201341. | Boisnic S, et al. Dermatology. 1999;199(Suppl 1):43\u201348. | Saurat JH, et al. J Invest Dermatol. 1994;103(6):770\u2013774.<\/p>\n

07 \u00b7 01 \u00b7 CLINICAL EVIDENCE \u2014 PHOTOAGING<\/p>\n

Human Photoaging: Improvement Comparable to Retinoic Acid<\/h2>\n\n\n\n\n
Study design<\/th>\nDetails<\/th>\n<\/tr>\n
Randomized controlled study<\/td>\nn=125; 18 weeks; optical profilometry; 0.05% retinaldehyde (n=40) versus 0.05% retinoic acid (n=40) versus vehicle (n=45).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
Dimension<\/th>\nResult<\/th>\n<\/tr>\n
Efficacy: comparable<\/td>\nBoth actives significantly reduced wrinkles and skin roughness; no statistically significant efficacy difference was observed between retinaldehyde and retinoic acid. An open study (n=32, four months) also found clear reductions in surface roughness and coarse wrinkles.<\/td>\n<\/tr>\n
Tolerance: better<\/td>\nLocal irritation was more frequent with retinoic acid and affected adherence. Retinaldehyde caused fewer local adverse reactions and supported better long-term adherence. Comparable efficacy plus better tolerance forms retinal’s core value proposition.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

In photoaged human skin, 0.05% retinaldehyde delivered wrinkle and roughness improvements comparable to 0.05% retinoic acid while maintaining significantly better local tolerance.<\/p>\n

Creidi P, et al. J Am Acad Dermatol. 1998;39(6):960\u2013965. | Creidi P, Humbert P. Dermatology. 1999;199(Suppl 1):49\u201352. | Mukherjee S, et al. Clin Interv Aging. 2006;1(4):327\u2013348.<\/p>\n

08 \u00b7 01 \u00b7 CLINICAL EVIDENCE \u2014 LONG-TERM<\/p>\n

Elasticity, Skin Thickness and Long-Term Performance<\/h2>\n

One-Year Instrumental Study: 0.05% Retinaldehyde<\/h3>\n

n=21 in the retinaldehyde group versus n=19 in the emollient-control group; high-resolution ultrasound plus echorheometry; measurements at baseline and one year.<\/p>\n\n\n\n\n\n\n
01<\/td>\nTemporal epidermal thickness increased significantly versus control (p < 0.01).<\/td>\n<\/tr>\n
02<\/td>\nSkin elasticity improved significantly versus control using suction rheology (p < 0.01).<\/td>\n<\/tr>\n
03<\/td>\nDermal thickness showed an increasing trend, while skin stiffness showed a decreasing trend.<\/td>\n<\/tr>\n
04<\/td>\nTolerance remained good throughout, supporting long-term daily use.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Increase in Dermal Thickness with a Non-Ablative Laser Regimen<\/h3>\n

Randomized double-blind study (n=16); 0.05% retinaldehyde versus vehicle for three months.<\/p>\n

<\/p>\n

Diridollou S, et al. Dermatology. 1999;199(Suppl 1):37\u201341. | Mordon data cited in Mukherjee S, et al. Clin Interv Aging. 2006;1(4):327\u2013348.<\/p>\n

09 \u00b7 01 \u00b7 TOLERANCE PROFILE<\/p>\n

High Activity Does Not Have to Mean High Irritation<\/h2>\n

<\/p>\n

In long-term clinical use, all three reaction rates were significantly lower with retinaldehyde; between-group analysis p < 0.0001.<\/p>\n\n\n\n\n\n\n
Setting<\/th>\nFinding<\/th>\n<\/tr>\n
Maximized conditions<\/td>\nRetinol and retinaldehyde showed similarly low irritation potential, while retinoic acid was significantly more irritating (p < 0.05). Laser Doppler confirmed an irritant effect for RA but not for ROL\/RAL (p = 0.001).<\/td>\n<\/tr>\n
Long-term clinical conditions<\/td>\nRetinaldehyde demonstrated clear retinoid biological activity, while rates of erythema, scaling and burning\/pruritus were significantly lower than with retinoic acid.<\/td>\n<\/tr>\n
Product implication<\/td>\nEfficacy and user experience can coexist, supporting sustained use and repurchase in premium retinoid products.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Fluhr JW, et al. Dermatology. 1999;199(Suppl 1):57\u201360. | Sachsenberg-Studer EM. Dermatology. 1999;199(Suppl 1):61\u201363.<\/p>\n

10 \u00b7 02 \u00b7 SYNERGY \u2014 BAKUCHIOL<\/p>\n

Why Bakuchiol<\/h2>\n

Bakuchiol is a plant-derived molecule with retinol-like gene-expression effects and multi-pathway skin activity. It is more than a natural retinol alternative; it represents an independent multi-pathway biology.<\/p>\n\n\n\n\n\n\n\n
Feature<\/th>\nDescription<\/th>\n<\/tr>\n
Source and class<\/td>\nDerived from the seeds and leaves of Psoralea corylifolia; a meroterpene phenol.<\/td>\n<\/tr>\n
Structure and function<\/td>\nChemically dissimilar to retinoids but functionally analogous to retinol.<\/td>\n<\/tr>\n
Mechanism<\/td>\nDoes not directly engage the RAR receptor pathway, helping explain its gentler tolerance profile.<\/td>\n<\/tr>\n
Use pattern<\/td>\nNo reported photosensitivity; suitable for morning and evening use.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Retinol-like gene expression, collagen and ECM support, antioxidant defense, inflammatory-signal modulation, skin homeostasis and barrier support, and pigment management<\/p>\n

Antioxidant defense \u00d7 inflammatory modulation \u00d7 ECM support \u00d7 homeostasis maintenance form a second renewal pathway beyond retinal.<\/p>\n

Chaudhuri RK, Bojanowski K. Int J Cosmet Sci. 2014;36(3):221\u2013230.<\/p>\n

11 \u00b7 02 \u00b7 SYNERGY \u2014 GENE EXPRESSION & COLLAGEN<\/p>\n

Bakuchiol: Retinol-Like Gene Expression \u00d7 ECM Support<\/h2>\n

<\/p>\n\n\n\n\n\n\n\n
Evidence dimension<\/th>\nFinding<\/th>\n<\/tr>\n
Collagen expression<\/td>\nHuman dermal fibroblast model; ELISA; untreated control set at 100%; 10 \u03bcg\/mL. Bakuchiol exceeded retinol for Collagen I and IV expression and was comparable for Collagen III.<\/td>\n<\/tr>\n
Gene-expression profile<\/td>\nDNA microarray analysis in a full-thickness reconstructed skin model showed highly similar overall regulation by bakuchiol and retinol, including upregulation of COL1A2, COL4A6, COL9A2, COL17A1, HAS3 and hydration-related AQP3.<\/td>\n<\/tr>\n
Non-classical RA pathway<\/td>\nNo effect on RA receptor genes such as RARB and RARG, suggesting action through non-classical retinoic-acid signaling and supporting a gentler irritation profile.<\/td>\n<\/tr>\n
12-week human study<\/td>\n0.5% bakuchiol significantly improved fine lines and wrinkles, pigmentation, elasticity, firmness and overall photodamage without the adverse effects commonly associated with retinol therapy.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Chaudhuri RK, Bojanowski K. Int J Cosmet Sci. 2014;36(3):221\u2013230. | Brown A, et al. Dermatol Ther (Heidelb). 2023;13(10):2299\u20132317.<\/p>\n

12 \u00b7 02 \u00b7 BAKUCHIOL \u2014 HUMAN EVIDENCE<\/p>\n

Comparable Efficacy to 0.5% Retinol with Better Tolerance<\/h2>\n

Study design: prospective, randomized, double-blind study; n=44; 12 weeks; 0.5% bakuchiol twice daily versus 0.5% retinol once daily; high-resolution facial imaging plus blinded dermatologist grading.<\/p>\n

<\/p>\n\n\n\n\n\n
Tolerance difference<\/th>\nDescription<\/th>\n<\/tr>\n
Retinol<\/td>\nMore facial scaling and stinging were reported.<\/td>\n<\/tr>\n
Bakuchiol<\/td>\nSuitable for morning and evening use, with no reported photosensitivity; offers wider design space for sensitive skin and higher-frequency use.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Head-to-head human evidence shows that bakuchiol was comparable to 0.5% retinol for both wrinkles and pigmentation, with better tolerance.<\/p>\n

Dhaliwal S, et al. Br J Dermatol. 2019;180(2):289\u2013296. | Draelos ZD, et al. J Drugs Dermatol. 2020;19(12):1181\u20131183.<\/p>\n

13 \u00b7 03 \u00b7 COMPLEMENTARY BIOLOGY<\/p>\n

Two Actives, Two Complementary Biological Systems<\/h2>\n\n\n\n\n\n\n\n\n\n
Dimension<\/th>\nRetinal<\/th>\nBakuchiol<\/th>\nComplementary value<\/th>\n<\/tr>\n
Core pathway<\/td>\nDirect precursor of retinoic acid \u2192 classical RAR retinoid signaling<\/td>\nRetinol-like transcriptional response via a non-classical RA pathway<\/td>\nDual-pathway coverage without full overlap<\/td>\n<\/tr>\n
Epidermal action<\/td>\nEpidermal renewal, keratinocyte differentiation and epidermal thickness<\/td>\nBarrier and homeostasis support; enhancement of differentiation-related genes<\/td>\nRenewal plus homeostasis<\/td>\n<\/tr>\n
ECM\/collagen<\/td>\nFibroblast function, new collagen deposition and MMP inhibition<\/td>\nCollagen I\/III\/IV expression and ECM support<\/td>\nSynthesis promotion \u00d7 degradation management<\/td>\n<\/tr>\n
Oxidation\/inflammation<\/td>\nManagement of photoaging-related matrix degradation<\/td>\nROS defense and inflammatory-signal modulation<\/td>\nA protective environment for high-efficiency activity<\/td>\n<\/tr>\n
Pigment\/blemish-prone skin<\/td>\nDepigmenting activity, keratinization renewal and C. acnes inhibition<\/td>\nPigmentation improvement and blemish-prone skin support<\/td>\nMulti-target clarity and tone management<\/td>\n<\/tr>\n
Tolerance<\/td>\nSignificantly better than retinoic acid<\/td>\nBetter than 0.5% retinol in a head-to-head study<\/td>\nLong-term-use friendliness for premium products<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

One pathway is a high-efficiency engine operating through classical RAR signaling; the other is a multi-pathway support system for homeostasis\u2014Retinal \u00d7 Bakuchiol complementary biology.<\/p>\n

14 \u00b7 03 \u00b7 DUAL-PATHWAY RENEWAL<\/p>\n

Dual-Pathway Renewal: A More Complete Renewal LogicClassical RAR signaling from retinal plus multi-pathway homeostasis support from bakuchiol<\/h2>\n\n\n\n\n\n\n
Retinal pathway<\/th>\nBakuchiol pathway<\/th>\n<\/tr>\n
One-step oxidation to retinoic acid<\/td>\nPlant-derived meroterpene phenol<\/td>\n<\/tr>\n
RAR-RXR heterodimer and target-gene transcription<\/td>\nRetinol-like transcriptional response plus antioxidant and inflammatory modulation; non-classical RA pathway, NF-\u03baB and ROS defense<\/td>\n<\/tr>\n
Epidermal renewal, keratinocyte differentiation, ECM remodeling, collagen homeostasis and MMP management<\/td>\nSkin homeostasis, barrier support, ECM support, photoaging defense and pigment management<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Dual-pathway retinoid renewal: epidermal renewal \u00b7 ECM support \u00b7 oxidative defense \u00b7 homeostasis maintenance.<\/p>\n

15 \u00b7 03 \u00b7 RETINAL + BAKUCHIOL \u2014 COMBINED HUMAN EVIDENCE<\/p>\n

Combined-System Human Study: Multidimensional Signals in 28 Days<\/h2>\n

Study design: open-label proof of concept; n=32 women, 65.6% with sensitive skin; once nightly for 28 days; a complex containing 0.1% liposomal retinal plus bakuchiol, with Vigna aconitifolia extract, niacinamide and melatonin.<\/p>\n

<\/p>\n\n\n\n\n\n
01<\/td>\n100% of subjects showed a reduction in crow’s-feet count; all 32 of 32 participants improved.<\/td>\n<\/tr>\n
02<\/td>\nGood tolerance: no significant changes in erythema or burning\/stinging; no participant, including those with sensitive skin, needed to alter the once-daily regimen.<\/td>\n<\/tr>\n
03<\/td>\nMethods: Cutometer\u00ae for firmness R0 and elasticity R2, Primos\u00ae-CR for wrinkles and VISIA\u00ae-CR for tone; D0\u2013D28 change from baseline; *p<0.05, ***p<0.001.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Note: These data describe the complete active system containing retinal plus bakuchiol and do not isolate the individual contribution of either ingredient.<\/p>\n

Brown A, et al. Dermatol Ther (Heidelb). 2023;13(10):2299\u20132317.<\/p>\n

16 \u00b7 03 \u00b7 FROM EFFICACY TO MECHANISM<\/p>\n

From Human Efficacy to Molecular Mechanism<\/h2>\n\n\n\n\n\n
01<\/td>\nEnhanced gene expression: In a full-thickness reconstructed human skin model, adding bakuchiol to 0.1% retinal further enhanced retinal’s regulation of keratinocyte-differentiation genes CASP14, KRT14 and TP63 and barrier genes FLG, CDSN and CLDN1. Several changes exceeded the 0.05% retinoic-acid control.<\/td>\n<\/tr>\n
02<\/td>\nNo increase in irritation potential: In a reconstructed human epidermis model, ET50 remained >24 hours for both 0.1% retinal alone and retinal + bakuchiol + Vigna aconitifolia extract, maintaining gentleness while improving performance.<\/td>\n<\/tr>\n
03<\/td>\nMechanistic interpretation: Bakuchiol upregulated CRABP-II and genes related to retinol metabolism, supporting efficient RA signaling and providing a complementary mechanistic explanation for combined-system efficacy.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Ex Vivo UV-Photodamaged Skin Model: Combined System<\/h3>\n\n\n\n\n\n\n\n\n\n
Marker<\/th>\nChange<\/th>\n<\/tr>\n
CRABP-II expression<\/td>\n+68%<\/td>\n<\/tr>\n
Hyaluronic acid<\/td>\n+71% versus UV-exposed skin<\/td>\n<\/tr>\n
Procollagen I<\/td>\n+33%<\/td>\n<\/tr>\n
Degraded collagen<\/td>\n\u221246% by CHP staining<\/td>\n<\/tr>\n
MMP-1 expression<\/td>\n\u221236%<\/td>\n<\/tr>\n
Total collagen<\/td>\n+16%, fully preventing UV-induced loss<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Scientific boundary: the evidence demonstrates multidimensional efficacy and complementary mechanisms for the combined system; it does not prove strict pharmacological synergy between the two ingredients.<\/p>\n

Brown A, et al. Dermatol Ther (Heidelb). 2023;13(10):2299\u20132317.<\/p>\n

17 \u00b7 04 \u00b7 DELIVERY \u2014 THE FORMULATION CHALLENGE<\/p>\n

Why Nano Delivery Is Needed<\/h2>\n\n\n\n\n\n\n\n
Retinal: high activity, high sensitivity<\/th>\nBakuchiol: the dispersion challenge of a lipophilic molecule<\/th>\n<\/tr>\n
Oxidation-sensitive aldehyde structure<\/td>\nLipophilic and naturally incompatible with high-water systems<\/td>\n<\/tr>\n
Light-sensitive, with activity loss under illumination<\/td>\nApplication and dispersion challenges in high-water systems<\/td>\n<\/tr>\n
Storage-stability challenges<\/td>\nFormula uniformity requires technical support<\/td>\n<\/tr>\n
Free active is vulnerable to the formulation environment<\/td>\nSystem compatibility requires optimization<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

High activity does not automatically equal high performance. An active must be protected, dispersed and delivered before efficacy can be realized in a formula. NanoActive™ encapsulation is designed for sensitive actives.<\/p>\n

18 \u00b7 04 \u00b7 DELIVERY \u2014 NANOACTIVE™ TECHNOLOGY<\/p>\n

Nano-Encapsulation Converts High Activity into High PerformanceNano-carriers encapsulate retinal and bakuchiol across protection, dispersion, delivery and formulation performance<\/h2>\n\n\n\n\n\n\n
01<\/td>\nProtection: Isolates and protects sensitive actives, reducing direct exposure to light, oxygen and the formulation environment.<\/td>\n<\/tr>\n
02<\/td>\nDispersion: Improves the dispersion and uniformity of lipophilic actives in high-water systems and optimizes compatibility.<\/td>\n<\/tr>\n
03<\/td>\nDelivery: Supports even delivery and distribution of actives on the skin.<\/td>\n<\/tr>\n
04<\/td>\nPerformance: Improves development flexibility across serums, emulsions, gels and other modern formats\u2014converting high activity into high formulation performance.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

19 \u00b7 04 \u00b7 FREE ACTIVE vs NANO-ENCAPSULATED<\/p>\n

Free Active vs Nano-Encapsulated<\/h2>\n\n\n\n\n\n\n\n
Free active<\/th>\nNanoActive™ encapsulation system<\/th>\n<\/tr>\n
Light\/oxygen\/formulation environment: direct exposure to degradation factors<\/td>\nActive encapsulation: retinal and bakuchiol loaded into nano-carriers<\/td>\n<\/tr>\n
Activity loss during storage and shelf life<\/td>\nProtection from light, oxygen and the formulation environment<\/td>\n<\/tr>\n
Dispersion challenge and limited uniformity in high-water systems<\/td>\nStable and uniform distribution in high-water systems<\/td>\n<\/tr>\n
Restricted delivery, reduced performance and narrower dosage-form choice<\/td>\nUniform delivery and greater design freedom across serums, emulsions, gels and other modern formats<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Specific technical parameters such as particle size, encapsulation efficiency, release profile and stability are subject to the PuriPharm product technical documents (TDS\/COA).<\/p>\n

20 \u00b7 05 \u00b7 APPLICATION \u2014 SKIN PERFORMANCE<\/p>\n

Wrinkles \u00b7 Firmness \u00b7 Elasticity \u00b7 Renewal<\/h2>\n\n\n\n\n\n\n
01<\/td>\nWrinkles and photoaging: RAR-driven epidermal renewal and dermal remodeling; a retinal + bakuchiol system reduced wrinkle count by 43.2% in 28 days (p<0.001); retinaldehyde produced wrinkle and roughness improvement comparable to retinoic acid in an n=125 randomized trial.<\/td>\n<\/tr>\n
02<\/td>\nFirmness and elasticity: Support for Collagen I\/III, elastin, ECM and MMP management; after 28 days, elasticity increased 13.9% (p<0.001) and firmness increased 5.6% (p<0.05); one year of 0.05% retinaldehyde significantly improved skin elasticity (p<0.01).<\/td>\n<\/tr>\n
03<\/td>\nEpidermal renewal: Regulation of keratinocyte differentiation and renewal, increased epidermal thickness (p<0.01), and improved texture and radiance\u2014the mechanistic basis for night renewal and Skin Longevity products.<\/td>\n<\/tr>\n
04<\/td>\nTone improvement: Retinal depigmenting activity and epidermal renewal plus bakuchiol-associated pigment improvement in 59% of subjects; tone uniformity increased 7.0% after 28 days (p<0.05).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Brown A, et al. Dermatol Ther (Heidelb). 2023;13(10):2299\u20132317. | Diridollou S, et al. Dermatology. 1999;199(Suppl 1):37\u201341. | Sorg O, et al. Dermatology. 2013;227(3):231\u2013237. | Dhaliwal S, et al. Br J Dermatol. 2019;180(2):289\u2013296.<\/p>\n

21 \u00b7 05 \u00b7 APPLICATION \u2014 ANTIOXIDANT \u00b7 BLEMISH-PRONE SKIN<\/p>\n

Antioxidant Defense and Blemish-Prone Skin Microenvironment ManagementUV\/pollution \u2192 ROS \u2192 oxidative stress \u2192 inflammatory signaling \u2192 increased MMP \u2192 collagen degradation; bakuchiol supports ROS defense, inflammatory modulation and MMP management<\/h2>\n

A Distinct Antibacterial Dimension of Retinal<\/h3>\n

<\/p>\n\n\n\n\n\n\n
01<\/td>\nIn vivo: daily 0.05% retinaldehyde reduced median viable C. acnes density by 10\u00b2 log\/cm\u00b2 after two weeks; vehicle had no effect.<\/td>\n<\/tr>\n
02<\/td>\nComedolytic and keratinization-renewal activity was observed in an animal model.<\/td>\n<\/tr>\n
03<\/td>\nBakuchiol antioxidant and inflammatory-modulating activity supports blemish-prone skin care.<\/td>\n<\/tr>\n
04<\/td>\nCosmetic language: clarity, balance, keratin renewal, blemish-prone skin care and microenvironment management.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Pech\u00e8re M, et al. Dermatology. 1999;199(Suppl 1):29\u201331. | Fort-Lacoste L, et al. Dermatology. 1999;199(Suppl 1):33\u201335. | Chaudhuri RK, Bojanowski K. Int J Cosmet Sci. 2014;36(3):221\u2013230.<\/p>\n

22 \u00b7 06 \u00b7 SKIN & SCALP LONGEVITY<\/p>\n

From Skin Longevity to Scalp Longevity<\/h2>\n

The scalp is an extension of facial skin. The same biology that drives facial renewal\u2014epidermal turnover, barrier homeostasis, oxidative-stress management and ECM support\u2014also applies to the scalp and follicular microenvironment.<\/p>\n

Skin Longevity \u2192 Scalp Longevity \u2192 Follicular Microenvironment<\/p>\n\n\n\n\n\n\n
Setting<\/th>\nCore biology<\/th>\n<\/tr>\n
Facial skin<\/td>\nRenewal, ECM, tone and homeostasis<\/td>\n<\/tr>\n
Scalp<\/td>\nKeratinization renewal, barrier, ROS and inflammatory microenvironment<\/td>\n<\/tr>\n
Follicular microenvironment<\/td>\nEpithelial homeostasis and perifollicular ECM<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
01<\/td>\nScalp aging involves declining barrier function, accumulated oxidative stress and changes in the follicular microenvironment, sharing a mechanistic framework with facial photoaging.<\/td>\n<\/tr>\n
02<\/td>\nThe dual-pathway logic of retinoid biology and antioxidant support naturally extends to scalp-renewal applications.<\/td>\n<\/tr>\n
03<\/td>\nThe NanoActive™ delivery system supports dispersion and delivery in lightweight scalp-serum formats.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Positioning: Scalp Longevity Active System | Scalp Longevity Serum | Advanced Scalp Renewal | Skin & Scalp Longevity<\/p>\n

23 \u00b7 06 \u00b7 SCALP & FOLLICLE BIOLOGY<\/p>\n

Scalp Renewal and Follicular Microenvironment SupportScalp epidermis, dermal\/follicular zone and follicular microenvironment<\/h2>\n\n\n\n\n\n\n
Level<\/th>\nSupport direction<\/th>\n<\/tr>\n
Scalp epidermis<\/td>\nKeratinization renewal, scalp barrier and homeostasis<\/td>\n<\/tr>\n
Dermal\/follicular zone<\/td>\nFollicular epithelium, perifollicular ECM and sebaceous glands<\/td>\n<\/tr>\n
Follicular microenvironment<\/td>\nROS management, inflammatory signaling and environmental stress<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
01<\/td>\nRetinoid biology and the follicle: Retinoic-acid synthesis is localized to specific regions of the follicle and sebaceous gland, including the stem-cell microenvironment. Precisely regulated RA levels are essential to follicular epithelial homeostasis.<\/td>\n<\/tr>\n
02<\/td>\nOxidative stress and scalp aging: Oxidative stress is an important driver of scalp and hair aging. Bakuchiol’s antioxidant and inflammatory-modulating properties provide protective support for the perifollicular microenvironment.<\/td>\n<\/tr>\n
03<\/td>\nProduct positioning: Focuses on the scalp-care environment and biological support\u2014scalp renewal, barrier maintenance and follicular microenvironment management\u2014without drug-like hair-growth or anti-hair-loss claims.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Everts HB. Biochim Biophys Acta. 2012;1821(1):222\u2013229. | Tr\u00fceb RM. Int J Trichology. 2009;1(1):6\u201314. | Tr\u00fceb RM. Int J Cosmet Sci. 2015;37(Suppl 2):25\u201330.<\/p>\n

24 \u00b7 07 \u00b7 APPLICATION MAP<\/p>\n

Multi-Setting Applications<\/h2>\n\n\n\n\n
Face<\/th>\nEye<\/th>\nScalp & Hair<\/th>\n<\/tr>\n
Advanced anti-aging serumsNight-renewal serumsLine-smoothing serumsFirming creamsSkin Longevity productsPhotoaging careTone-radiance careBlemish-prone skin care<\/td>\nEye serumsLine-smoothing eye creamsCrow’s-feet managementIn the combined-system study, 100% of subjects showed fewer crow’s feet after 28 days<\/td>\nScalp serumsAnti-aging scalp serumsScalp Longevity SerumHair Vitality SerumNight scalp careFollicular microenvironment care<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Premium concepts: Retinoid Cycling | Skin Longevity | Scalp Longevity | Healthy Aging | Preventive Aging | Night Renewal<\/p>\n

25 \u00b7 THE PLATFORM<\/p>\n

A Next-Generation Dual-Pathway Retinoid Renewal PlatformAdvanced retinal biology + complementary multi-pathway bakuchiol activity + NanoActive™ nano delivery<\/h2>\n\n\n\n\n\n\n\n
Platform value<\/th>\nDescription<\/th>\n<\/tr>\n
Performance<\/td>\nOne oxidation step to RAR signaling, supported by a complete human-efficacy evidence chain.<\/td>\n<\/tr>\n
Complementary biology<\/td>\nRetinol-like gene expression \u00d7 antioxidant defense \u00d7 homeostasis support.<\/td>\n<\/tr>\n
Delivery<\/td>\nProtection, dispersion and delivery convert high activity into high formulation performance.<\/td>\n<\/tr>\n
Skin + scalp applications<\/td>\nA platform spanning both Skin Longevity and Scalp Longevity.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

NanoActive™ Retinal-Bakuchiol: Retinoid performance, redefined.<\/p>\n

PuriActives\u00ae and NanoActive™ are trademarks of PuriPharm Co., Ltd. This material is intended solely for technical communication concerning cosmetic ingredients.<\/p>\n

26 \u00b7 SCIENTIFIC REFERENCES<\/p>\n

Scientific References<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
01<\/td>\nSiegenthaler G, Saurat JH, Ponec M. Retinol and retinal metabolism. Relationship to the state of differentiation of cultured human keratinocytes. Biochem J. 1990;268(2):371\u2013378.<\/td>\n<\/tr>\n
02<\/td>\nSaurat JH, et al. Topical retinaldehyde on human skin: biologic effects and tolerance. J Invest Dermatol. 1994;103(6):770\u2013774.<\/td>\n<\/tr>\n
03<\/td>\nCreidi P, et al. Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol. 1998;39(6):960\u2013965.<\/td>\n<\/tr>\n
04<\/td>\nCreidi P, Humbert P. Clinical use of topical retinaldehyde on photoaged skin. Dermatology. 1999;199(Suppl 1):49\u201352.<\/td>\n<\/tr>\n
05<\/td>\nDiridollou S, et al. Efficacy of topical 0.05% retinaldehyde in skin aging by ultrasound and rheological techniques. Dermatology. 1999;199(Suppl 1):37\u201341.<\/td>\n<\/tr>\n
06<\/td>\nBoisnic S, et al. Repair of UVA-induced elastic fiber and collagen damage by 0.05% retinaldehyde cream in an ex vivo human skin model. Dermatology. 1999;199(Suppl 1):43\u201348.<\/td>\n<\/tr>\n
07<\/td>\nPech\u00e8re M, et al. Antibacterial activity of retinaldehyde against Propionibacterium acnes. Dermatology. 1999;199(Suppl 1):29\u201331.<\/td>\n<\/tr>\n
08<\/td>\nFort-Lacoste L, et al. Comedolytic effect of topical retinaldehyde in the rhino mouse model. Dermatology. 1999;199(Suppl 1):33\u201335.<\/td>\n<\/tr>\n
09<\/td>\nFluhr JW, et al. Tolerance profile of retinol, retinaldehyde and retinoic acid under maximized and long-term clinical conditions. Dermatology. 1999;199(Suppl 1):57\u201360.<\/td>\n<\/tr>\n
10<\/td>\nSachsenberg-Studer EM. Tolerance of topical retinaldehyde in humans. Dermatology. 1999;199(Suppl 1):61\u201363.<\/td>\n<\/tr>\n
11<\/td>\nMukherjee S, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327\u2013348.<\/td>\n<\/tr>\n
12<\/td>\nSorg O, et al. The potential depigmenting activity of retinaldehyde. Dermatology. 2013;227(3):231\u2013237.<\/td>\n<\/tr>\n
13<\/td>\nKwon HS, et al. Efficacy and safety of retinaldehyde 0.1% and 0.05% creams used to treat photoaged skin: a randomized double-blind controlled trial. J Cosmet Dermatol. 2018;17(3):471\u2013476.<\/td>\n<\/tr>\n
14<\/td>\nChaudhuri RK, Bojanowski K. Bakuchiol: a retinol-like functional compound revealed by gene expression profiling and clinically proven to have anti-aging effects. Int J Cosmet Sci. 2014;36(3):221\u2013230.<\/td>\n<\/tr>\n
15<\/td>\nDhaliwal S, et al. Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing. Br J Dermatol. 2019;180(2):289\u2013296.<\/td>\n<\/tr>\n
16<\/td>\nBrown A, et al. Natural retinol analogs potentiate the effects of retinal on aged and photodamaged skin: results from in vitro to clinical studies. Dermatol Ther (Heidelb). 2023;13(10):2299\u20132317.<\/td>\n<\/tr>\n
17<\/td>\nDraelos ZD, et al. Clinical evaluation of a nature-based bakuchiol anti-aging moisturizer for sensitive skin. J Drugs Dermatol. 2020;19(12):1181\u20131183.<\/td>\n<\/tr>\n
18<\/td>\nFisher GJ, et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature. 1996;379(6563):335\u2013339.<\/td>\n<\/tr>\n
19<\/td>\nEverts HB. Endogenous retinoids in the hair follicle and sebaceous gland. Biochim Biophys Acta. 2012;1821(1):222\u2013229.<\/td>\n<\/tr>\n
20<\/td>\nTr\u00fceb RM. Oxidative stress in ageing of hair. Int J Trichology. 2009;1(1):6\u201314.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

NanoActive™Retinal \u2013 Bakuchiol Nano-Encapsulated […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[25],"tags":[41,35,38],"_links":{"self":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1385"}],"collection":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1385"}],"version-history":[{"count":1,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1385\/revisions"}],"predecessor-version":[{"id":1386,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1385\/revisions\/1386"}],"wp:attachment":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1385"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}